TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Objective. The aims of this study were to investigate the impact of TAK-242 on the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear transcription factor-kappa B (NF-kappa B) signal transduction pathway in rats with hepatic fibrosis (HF) using the liver gut axis and to investigate the molecular mechanism of its intervention on HF. Methods. SPF grade SD male rats were randomly allocated to the control, model, and TAK-242 groups. For 8 weeks, the model and TAK-242 groups received 3 mL.kg(-1) (the initial dose 5 mL.kg(-1)) intraperitoneal injections of 40% CCL4 olive oil solution. TAK-242 (5 mg.kg(-1)) was administered once a day for 5 days after modeling. The pathological alterations of liver and small intestine tissues in each group were observed using H & E and Masson staining. ELISA was used to measure serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin (DBIL), total bilirubin (TBIL), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha). RT-qPCR was utilized to identify the mRNA expression level of IL-1 beta, IL-6, TNF-alpha, TLR4, MyD88, and NF-kappa B in rat liver and small intestine tissues. The protein level of IL-1 beta, IL-6, TNF-alpha, TLR4, MyD88, and NF-kappa B protein in rat liver and small intestine tissues was determined utilizing Western blot and IHC. Results. TAK-242 significantly reduced AST, ALT, TBIL, and DBIL expression in HF rats' serum (P < 0.01) and alleviated liver tissue injury. Hematoxylin-eosin (H & E) and Masson staining revealed inflammatory cell infiltration and fibrous proliferation in the liver and small intestine tissue in the model group and partial cell swelling in the TAK-242 group, which indicated a considerable improvement compared to the model group. RT-qPCR, Western blot, and IHC data indicated that TAK-242 reduced the IL-1 beta, IL-6, TNF-alpha, TLR4, MyD88, and NF-kappa B expression in the liver and small intestine tissues of HF rats. Conclusion. TAK-242 might downregulate the TLR4/MyD88/NF-kappa B signal pathway through the liver-gut axis, suppress the inflammatory response, and eventually alleviate HF in rats.